Generate Biomedicines GENB Insider Ownership

Updated Oct 10, 2026

Over the past 12 months, Generate Biomedicines insiders bought $75.3 million of stock on the open market (4.71Mn shares) and sold $16,002 (1K shares).

• Counted by insider, open-market buying of GENB stock in the past 12 months came from 5 insiders and selling from one insider.
• Among GENB insiders, Noubar Afeyan (Director and 10% owner) bought the most stock on the open market in the past 12 months: $75 million (4.69Mn shares), most recently on March 2, 2026.
• On the selling side, Frances Arnold (Director) was the top open-market seller of Generate Biomedicines over the past 12 months, with $16,002 sold (1K shares) and the latest sale on September 1, 2026.
• In transactions other than open-market trades, Generate Biomedicines insiders acquired 34.35Mn shares through option exercises and conversions over the past 12 months.
• Per Business Quant, GENB insiders together hold 40.5Mn shares based on their latest Form 4 filings, or 31.58% of the 128.27Mn shares outstanding; that total is up 0.57% from 40.27Mn shares at the end of Q2 2026.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 98.01% (39.7Mn shares) of Generate Biomedicines' insider total, with the other 1.99% (805.68K shares) held directly.
• Holdings in Generate Biomedicines stock are reported by 7 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Generate Biomedicines' three largest insider shareholders, based on their latest Form 4 filings, are Noubar Afeyan (Director and 10% owner, 37.66Mn shares), Michael Nally (Chief Executive Officer, 1.89Mn shares) and Stephane Bancel (Director, 724.16K shares).
• The largest insider, Noubar Afeyan, holds 92.97% of GENB's insider total.
• Over the trailing 12 months, 14 insiders reported transactions in GENB stock across 17 Form 4 filings.
• This summary of Generate Biomedicines insider activity covers Form 4 filings through September 3, 2026.